Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03691636
Recruitment Status : Recruiting
First Posted : October 2, 2018
Last Update Posted : October 2, 2018
Sponsor:
Information provided by (Responsible Party):
D.E.L., LLC

Brief Summary:
This is a single-center, randomized, controlled trial to evaluate the safety and efficacy of eyelash prostheses versus 5.0% Lifitegrast BID, in 40 patients (20 randomized to each of two arms of the study) evaluated at 3 weeks and 5 weeks, respectively, after initiation of treatment.

Condition or disease Intervention/treatment Phase
Dry Eye Device: Eyelash prostheses Device: 5.0% Lifitegrast Ophthalmic Solution Not Applicable

Detailed Description:

This is a single center, randomized, controlled clinical trial to evaluate the tolerability, efficacy, and safety of eyelash prostheses over a 3-week period versus Xiidra BID over a 5 week period in subjects with self-reported DED. 40 subjects will be randomized to either eyelash prostheses or Xiidra, in a 1:1 ratio.

At Visit 1 (screening), informed consent will be obtained from subjects and eligibility will then be determined. All pre-treatment assessments will be done at this visit. Randomization will occur. If randomized to receive Xiidra eye drops, a prescription will be written and the treatment will be started right away. If randomized to eyelash prostheses, then a second study visit will be made approximately 2 weeks later.

Visit 2 (Eyelash Prostheses application) Subjects randomized to receive eyelash prostheses will have them applied approximately 2 weeks after the screening and randomization visit.

Visit 3 (Final visit) will be 3 weeks post eyelash prosthesis placement and 5 weeks post Xiidra eye drop initiation. This was done to compare the maximal treatment effect between the two groups. All subjects will undergo post-treatment assessments.

At each visit, patients will be asked to report any adverse events.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective randomized clinical trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Center, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Eyelash Prostheses Compared to 5.0% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease.
Estimated Study Start Date : October 2, 2018
Estimated Primary Completion Date : April 2, 2019
Estimated Study Completion Date : May 1, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Lifitegrast

Arm Intervention/treatment
Experimental: Eyelash Prostheses
Each subject in this arm will receive eyelash prostheses according to a specified algorithm by a certified eyelash extensions.
Device: Eyelash prostheses
Eyelash prostheses are essentially specialized eyelash extensions

Active Comparator: 5.0% Lifitegrast Ophthalmic Solution
Each subject in this arm will receive 5.0% Lifitegrast eye drops BID
Device: 5.0% Lifitegrast Ophthalmic Solution
5.0% Lifitegrast Ophthalmic Solution




Primary Outcome Measures :
  1. Non-inferior change from baseline in tear break up time as measured by the Oculus Keratograph in the interventional subjects compared to the active control subjects [ Time Frame: The primary endpoint will be assessed 3 weeks after eyelash prosthesis placement in the interventional arm and 5 weeks after initiation of eye drops in the active comparator arm ]
    A non-inferiority endpoint in tear break up time


Secondary Outcome Measures :
  1. Non-inferior change in tear meniscus height as measured by the Oculus Keratograph in the treatment subjects compared to control subjects [ Time Frame: The secondary endpoint will be assessed 3 weeks after eyelash prosthesis placement in the interventional arm and the interventional arm and 5 weeks after initiation of eye drops in the active comparator arm ]
    Non-inferiority endpoint in tear meniscus height

  2. Non-inferior change from baseline in SPEED II questionnaire in the treatment subjects compared to the control subjects [ Time Frame: The secondary endpoint will be assessed 3 weeks after eyelash prosthesis placement in the interventional arm and the interventional arm and 5 weeks after initiation of eye drops in the active comparator arm ]
    Non-inferiority endpoint in the SPEED II questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Self-reported dry eye symptoms
  2. Tear Break Up Time of less than 10 seconds as assessed by the Oculus Keratograph (see Appendix A).
  3. SPEED II Score greater than 25
  4. Men or Women, age between 50 and 90 inclusive
  5. Willingness to undergo both pre-treatment and post-treatment testing per the protocol
  6. Willingness to endure the 2-3 hour time required to place eyelash extensions, if randomized to this treatment arm
  7. Willingness to use eye drops for dry eyes and fill a prescription through insurance coverage, if randomized to this treatment arm
  8. Willingness to attend all study visits
  9. Willingness to sign informed consent and liability waiver

    -

Exclusion Criteria:

  1. Absence of eyelashes
  2. Eyelash disease such as clinically significiant demodex, blepharitis, meibomitis
  3. Be unable or unwilling to give written informed consent and/or to comply with study procedures.
  4. Have any known hypersensitivity or contraindication to study treatments (including excipients), topical anesthetics or vital dyes.
  5. Be unable to demonstrate correct instillation of over the counter (OTC) ocular lubricant during Visit 1.
  6. Have clinically significant ocular surface disease in either eye (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with study safety procedures, or assessments.
  7. Have clinically significant systemic disease (e.g., uncontrolled diabetes, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study at Visit 1 and 2.
  8. Current use of Restasis or Xiidra at the time of Visit 1
  9. Changes in the dose of, or the initiation of, any medications that are known to affect dry eyes within 90 days of Visit 1 or during the duration of the study.
  10. Any history of Herpes simplex of Herpes zoster affecting the eye or head.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03691636


Contacts
Layout table for location contacts
Contact: Nancy M Holekamp, MD 314-378-9552 nholekamp@gmail.com
Contact: Michael Korenfeld, MD 636-390-3999 michaelkorenfeld@hotmail.com

Locations
Layout table for location information
United States, Missouri
Comprehensive Eye Care Recruiting
Washington, Missouri, United States, 63039
Contact: Michael Korenfeld, MD    636-390-3999    michaelkorenfeld@hotmail.com   
Principal Investigator: Michael Korenfeld, MD         
Sub-Investigator: Rita Hindmon         
Sponsors and Collaborators
D.E.L., LLC
Investigators
Layout table for investigator information
Principal Investigator: Michael Korenfeld, MD Comprehensive Eye Care

Layout table for additonal information
Responsible Party: D.E.L., LLC
ClinicalTrials.gov Identifier: NCT03691636    
Other Study ID Numbers: D.E.L. 002
First Posted: October 2, 2018    Key Record Dates
Last Update Posted: October 2, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to share data

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Eye Diseases
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Lifitegrast
Ophthalmic Solutions
Pharmaceutical Solutions